✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the J.P. Morgan Healthcare Conference on January 14, 2026, highlighting the company’s autoimmune-focused cell therapy strategy to the investment community. The presentation signals Kyverna’s continued engagement with global healthcare investors as it advances its clinical
✨ Onyx Summary Rocket Pharmaceuticals, Inc. announced that CEO Gaurav Shah will present and host investor meetings at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The appearance provides investors with an update opportunity as the company advances multiple late- and early-stage gene therapy
✨ Onyx Summary ImmunityBio announced that OncoDaily has named its founder and executive chairman, Patrick Soon-Shiong, to The 100 Most Influential People in Oncology in 2025. The recognition underscores Soon-Shiong’s long-standing impact on oncology research and leadership, reinforcing ImmunityBio’s scientific credibility and visibility within the global cancer research and
✨ Onyx Summary Guardant Health said it will present and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12. The presentation provides the company with exposure to a major healthcare investment audience through a live and archived webcast
✨ Onyx Summary enGene Holdings Inc. reported full-year 2025 financial results and a business update, highlighting completion of enrollment in the pivotal LEGEND cohort for detalimogene in BCG-unresponsive NMIBC and a cash position of $342.4 million, extending operating runway into the second half of 2028. The company outlined plans to
✨ Onyx Summary Sinaptica Therapeutics announced the completion of its Scientific Advisory Board, assembling experts across neuroscience, clinical development, neuromodulation, patient advocacy, and commercialization to guide the company through its upcoming pivotal Alzheimer’s disease trial. The expanded board strengthens Sinaptica’s strategic positioning at a key inflection point, supporting clinical
✨ Onyx Summary A consortium led by Verily secured a two-year, $9.2 million renewal of the NIH System Biology award to advance FAIRplex, a platform enabling researchers to find, access, and analyze multimodal data from Accelerating Medicines Partnership (AMP®) projects. The renewal shifts FAIRplex from initial development to operational deployment
✨ Onyx Summary Geron Corporation granted stock options covering 320,000 shares to a newly hired employee as an inducement award, with options priced at the December 17, 2025 closing share price and vesting over four years in accordance with Nasdaq rules and the company’s inducement equity plan. FOSTER CITY,
✨ Onyx Summary Perspective Therapeutics announced that Chief Executive Officer Thijs Spoor will present at the J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. SEATTLE, Dec. 18, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering
✨ Onyx Summary Kyverna Therapeutics priced an underwritten public offering of 13.33 million shares at $7.50 per share, generating expected gross proceeds of approximately $100 million, with an option for underwriters to purchase up to an additional 2.0 million shares. The offering, led by J.P. Morgan, Leerink
✨ Onyx Summary Legend Biotech Corporation announced that CEO Ying Huang will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and replay available via the company’s investor relations website. SOMERSET, N.J.,Dec. 17, 2025 – Legend Biotech
✨ Onyx Summary ImmunityBio reported long-term Phase 2/3 QUILT-3.032 data showing that ANKTIVA plus BCG delivered durable disease-free, progression-free, and disease-specific survival, with high cystectomy avoidance through 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer. Published in The Journal of Urology, the findings extend evidence
✨ Onyx Summary nChroma Bio said it has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of CRMA-1001 for the treatment of chronic hepatitis B. The approval advances a novel epigenetic silencing approach into the clinic, positioning the company to address a large unmet global
✨ Onyx Summary Kyverna Therapeutics announced the launch of an underwritten public offering of $100 million of common stock, with an option for underwriters to purchase up to an additional $15 million of shares, subject to market conditions. The financing is intended to be conducted under Kyverna’s existing shelf registration
✨ Onyx Summary Kyverna Therapeutics reported positive topline data from the registrational Phase 2 KYSA-8 trial showing that mivocabtagene autoleucel (miv-cel), a CD19-targeting CAR T-cell therapy, delivered statistically significant and sustained improvements in mobility, disability, and stiffness in patients with stiff person syndrome after a single dose. The results support Kyverna’
✨ Onyx Summary Kyverna Therapeutics announced it will host a live webcast and conference call on December 15, 2025, to review topline results from the registrational Phase 2 KYSA-8 trial evaluating KYV-101 in patients with stiff person syndrome. EMERYVILLE, Calif., Dec. 14, 2025 – Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical
